Relapsed or Refractory AL Amyloidosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 

AL amyloidosis, also known as amyloid light chain amyloidosis, is a rare condition where a small B-cell clone, often a plasma cell clone, produces monoclonal light chains. These light chains can cause organ toxicity and deposit in tissues as amyloid fibrils. The clinical manifestations depend on the affected organs, but symptoms are often recognized late. Patients diagnosed at advanced stages, especially when heart involvement is present, face a high risk of death within a few months. Hematologists can screen individuals with known monoclonal gammopathy for amyloid organ dysfunction and damage, allowing for a presymptomatic diagnosis. Detectable monoclonal gammopathy and elevated biomarkers of organ involvement precede symptoms. Treatment aims to target the underlying clone and achieve early and profound hematologic and organ response long-term. Close monitoring of hematologic response is essential to identify nonresponders and shift them to rescue treatments. Autologous Stem Cell Transplantation is an option for approximately one-fifth of patients upfront or after bortezomib-based conditioning. Bortezomib is the backbone of therapy for patients ineligible for transplantation. Daratumumab + Bortezomib is emerging as a novel standard of care. Immune-modulatory drugs are commonly used for relapsed/refractory disease. Daratumumab is an effective option for relapsed/refractory cases. Patients who reach excellent partial response (VGPR) may tolerate a gradual rise in free light chains (dFLC), assuming their dFLC was not <50 mg/L at diagnosis. Second-line therapy for relapsed/refractory AL amyloidosis (RRAL) may include daratumumab or daratumumab-based therapy.

Thelansis’s “Relapsed or Refractory AL Amyloidosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Relapsed or Refractory AL Amyloidosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Relapsed or Refractory AL Amyloidosis across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Relapsed or Refractory AL Amyloidosis Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Relapsed or Refractory AL Amyloidosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033